GlassScriptPhysician profile
Ankit V Patel
NPI 1790046373
$1,392.17
in general payments reported to CMS, 2019-2025
19 companies · $35.46 in 2025
The $35.46 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $13.64 · 2021: $23.82 · 2022: $46.75 · 2023: $329 · 2024: $723 · 2025: $35.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Education: $36.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.89 |
| Education | $36.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.83 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.47 | 2021-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $107.20 | 2019-2024 | Entyvio |
| Ardelyx, INC. | $104.36 | 2023-2024 | Ibsrela |
| Sandoz INC. | $98.55 | 2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $90.27 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $47.78 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $47.45 | 2023-2024 | Dificid |
| Celltrion USA INC. | $36.27 | 2024 | Zymfentra |
| Janssen Biotech, INC. | $33.69 | 2023-2024 | Stelara |
| Intercept Pharmaceuticals, INC. | $28.40 | 2019-2024 | |
| Braintree Laboratories, INC. | $19.19 | 2024 | Sutab, Suflave |
| Stryker Corporation | $18.30 | 2025 | Flowtriever |
| Phathom Pharmaceuticals, INC. | $18.28 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $17.16 | 2025 | Inspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.60 | 2024 | Omvoh |
| Celgene Corporation | $15.62 | 2024 | Zeposia |
| Evoke Pharma, INC. | $14.43 | 2024 | |
| Boston Scientific Corporation | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.